Journal
BIOSCIENCE REPORTS
Volume 41, Issue 12, Pages -Publisher
PORTLAND PRESS LTD
DOI: 10.1042/BSR20211640
Keywords
-
Categories
Funding
- National Natural Science Foundation [81960456, 82002660, 81760445, 81760446]
- Jiangxi Province Department of Education Science and Technology Research Project, China [GJJ190018]
Ask authors/readers for more resources
The study established a ferroptosis-related signature (FRSig) to evaluate the prognosis of glioma patients and its role in the microenvironment. By stratifying patient groups and utilizing methods like single-sample gene set enrichment analysis (ssGSEA), a diagnostic model related to clinical outcomes was developed.
Background: Glioma is a malignant intracranial tumor and the most fatal cancer. The role of ferroptosis in the clinical progression of gliomas is unclear. Method: Univariate and least absolute shrinkage and selection operator (Lasso) Cox regres-sion methods were used to develop a ferroptosis-related signature (FRSig) using a cohort of glioma patients from the Chinese Glioma Genome Atlas (CGGA), and was validated us-ing an independent cohort of glioma patients from The Cancer Genome Atlas (TCGA). A single-sample gene set enrichment analysis (ssGSEA) was used to calculate levels of the immune infiltration. Multivariate Cox regression was used to determine the independent prognostic role of clinicopathological factors and to establish a nomogram model for clini-cal application. Results: We analyzed the correlations between the clinicopathological features and ferroptosis-related gene (FRG) expression and established an FRSig to calculate the risk score for individual glioma patients. Patients were stratified into two subgroups with distinct clinical outcomes. Immune cell infiltration in the glioma microenvironment and immune-related indexes were identified that significantly correlated with the FRSig, the tu-mor mutation burden (TMB), copy number alteration (CNA), and immune checkpoint ex-pression was also significantly positively correlated with the FRSig score. Ultimately, an FRSig-based nomogram model was constructed using the independent prognostic factors age, World Health Organization (WHO) grade, and FRSig score. Conclusion: We established the FRSig to assess the prognosis of glioma patients. The FRSig also represented the glioma microenvironment status. Our FRSig will contribute to improve patient management and individualized therapy by offering a molecular biomarker signature for precise treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available